Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given a consensus recommendation of “Hold” by the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $73.00.

Several equities analysts recently weighed in on HALO shares. Morgan Stanley lifted their price target on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, August 18th. JMP Securities boosted their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price on the stock in a research report on Tuesday, October 14th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the transaction, the director owned 46,952 shares in the company, valued at $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $55,285,726.65. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 108,227 shares of company stock valued at $7,779,595. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $32,000. Newbridge Financial Services Group Inc. purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $32,000. SVB Wealth LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at about $33,000. Bessemer Group Inc. lifted its stake in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares in the last quarter. Finally, Employees Retirement System of Texas purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $67.03 on Wednesday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The stock has a market capitalization of $7.84 billion, a price-to-earnings ratio of 15.34, a PEG ratio of 0.36 and a beta of 1.16. The firm’s 50 day simple moving average is $71.56 and its 200-day simple moving average is $62.09. Halozyme Therapeutics has a 12 month low of $42.01 and a 12 month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the prior year, the firm posted $0.91 earnings per share. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.